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INTRODUCTION
Transforming growth factor- (TGFβ) acts as a po-
tent tumor suppressor and tumor promoter in a con-
text-dependent manner [1]. Tumor suppressive func-
tions include inhibition of cell proliferation, induction 
of apoptosis and regulation of autophagy. As tumors 
develop they switch their response to TGFβ and utilize 
this factor as a potent promoter of cell motility, inva-
sion, metastasis and tumor stem cell maintenance. 
It has been widely proved that misregulation of TGFβ, 
i .e.  TGFβ over-expression,  TGFβ receptor 
or Smad2/4 loss or mutation, can result in tumor de-
velopment [2]. Epidermal Growth Factor (EGF) is an-
other potent regulator of cell functions, with predom-
inantly pro-mitogenic role in tumorigenesis [3]. EGF 
promotes also cell survival, angiogenesis and differ-
entiation. Deregulation of human epidermal growth 
factor receptor (ErbB/HER) pathways by over-expres-
sion or constitutive activation can promote tumorigen-
esis, including angiogenesis and metastasis and 
is associated with poor prognosis in many human 
malignancies [4].
TGF and EGF initiate signaling events via acting 
on different receptors. However, recent reports indi-
cate that many of the components in their intracellular 
signaling pathways may be targeted by both growth 
factors. Understanding the molecular mechanisms 
of how TGFβ and EGF signaling interact at different 
stages of cancer is important for development of novel 
therapeutics. In this report, we focus on TGF and EGF 
signaling, with emphasis on the cross-talk between 
their regulatory pathways.
TGFβ SIGNALING AND CANCER
TGFβ signaling is initiated by the binding of TGFβ 
ligands to type II TGFβ receptor (TR-II). TβR-II forms 
a dimer and recruits type I TGF receptor (TR-I). 
Upon formation of a heterotetrameric complex 
of 2 TR-II and 2 TR-I, TR-I becomes activated, and 
phosphorylates a number of substrates. TGF-β elicits 
its biological effects by coordinated activation of the 
well studied canonical Smad pathway and several 
non-Smad signaling pathways (Fig. 1) [5]. In Smad-
dependent pathway, TβR-I mediated C-terminal 
phosphorylation of the receptor-regulated Smads, 
Smad2 at Ser465/476 and Smad3 at Ser433/435. 
Following phosphorylation, Smads 2 and 3 form het-
eroligomeric complexes with the co-Smad, Smad4, 
enter the nucleus, and in cooperation with cofactors 
and other sequence specific transcription factors both 
positively and negatively regulate gene expression. 
TGFβ also activate several Smad-independent path-
ways, including TAK1, RAS, PI3K, PLC, PP2A, SHC, 
Rho, Rac and protein synthesis via eEF1A1. TGFβ plays 
dual role in cancer development. It acts as a tumor 
suppressor in normal epithelial cells and in early stage 
of tumor progression. In advanced cancers the growth 
inhibitory function of TGFβ is selectively lost, and TGFβ 
induces many activities that lead to growth, invasion 
and metastasis of cancer cells [1, 2]. 
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Fig. 1. Schematic presentation TGFβ signaling pathway. TGFβ 
binds the type II TGFβ receptor (TβRII) and this complex is able 
to recruit and transactivate the type I TGFβ receptor (TβRI). The 
ligand-bound TβRII/TβRI receptor complex subsequently acti-
vates downstream Smad-dependent and Smad-independent 
signaling. In the Smad-dependent signaling cascade, acti-
vated Smad2 and Smad3 are able to bind Smad4 as homo- and 
heterodimers, then translocate to the nucleus where they act 
as co-activators or co-repressors of transcription. The Smad-
independent pathways regulated by TGFβ are known to include 
Shc, RHO, RAC/CDC42, RAS, TAK1, PI3K, PAR6, PP2A and 
protein synthesis (eEF1A1).
Alterations in TGFβ signaling have been associated 
with solid tumor initiation, progression and metastasis 
[1, 2, 5]. TGFβ1 overexpression has been reported 
in breast, colon, esophageal, gastric, lung, pancre-
atic and prostate cancer. High levels of TGFβ1 have 
also been detected in the serum of patients with 
colon and liver cancer. However, downstream sig-
naling component mutations, loss of expression 
and attenuation have been detected in many solid 
carcinomas. In particular, it has been shown that the 
central mediators of TGFβ signaling TGFβR1, TGFβR2, 
Smad2 and Smad4 are frequently lost, mutated or at-
tenuated in human carcinomas. Intragenic mutation, 
down-regulation and loss of TGFβR2 expression have 
been observed in bladder, breast, colon, esophageal, 
lung, ovarian, pancreatic and prostate cancers. Loss 
of expression, down-regulation and mutation have also 
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been demonstrated in association with TGFβR1 in bili-
ary, bladder, breast, gastric, liver, ovarian, pancreatic 
and prostate cancers. Smad4 mutation, deletion and 
loss of expression has been reported in biliary, blad-
der, breast, cervical, colon esophageal, intestine, liver, 
lung, ovarian and pancreatic cancers. Smad2 de-
regulation seems to be less frequent than Smad4, 
however mutation and deletion has been observed 
in cervical, colon, liver and lung cancer. Interestingly, 
with the exception of gastric, extravillus trophoblast 
and colon cancer, Smad3 is often maintained in hu-
man carcinomas suggesting that it may have a role 
different from Smad2 in carcinoma cells that favors 
tumor progression.
EGF SIGNALING AND CANCER
The epidermal growth factor (EGF) receptor fam-
ily consists of four related receptors: EGFR (EGFR 
or ErbB1), ErbB2 (Neu/HER2), ErbB3 (HER3) and 
ErbB4 (HER4). These receptors are differently acti-
vated by ligands including EGF, TGF, amphiregulin 
(SDGF), cellulin (BTC), epiregulin (EREG), heparin-
binding EGF-like growth factor (HB-EGF) and the 
neuregulins (NRG1, NRG2, NRG3 and NRG4) [3, 6]. 
Binding of ligands to the extracellular domains of ErbB 
receptors initiates their homodimerization or heterodi-
merization with other ErbB receptors, and phosphory-
lation of tyrosine residues within their cytoplasmic 
domains. Autophosphorylation of receptors leads 
to a number of protein-protein interactions, that in turn 
activate downstream growth and survival signals such 
as the mitogen-activated protein kinase (MAPK) and 
phosphoinositol 3-kinase/v-akt murine thymoma viral 
oncogene homolog (PI3K/AKT) pathways (Fig. 2) [6]. 
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Fig. 2. Schematic presentation of EGFR signaling pathway. 
EGFR signaling pathway is initiated by binding of ligands to the 
extracellular domain of ErbB receptors, which results in receptor 
dimerization, tyrosine kinase activation and transphosphoryla-
tion (P). The activated ErbB receptors are able to interact with 
different signaling molecules that transmit the signal in the cell, 
including Chl, Src, PI3K, PLC, STAT, Ras, Nck-Jnk and SHP1/2.
The EGF family members play important roles 
in normal physiological processes including ontogeny, 
morphogenesis, migration, differentiation and prolifer-
ation. Deregulation of EGF family members and related 
signaling molecules can contribute to tumorigenesis, 
invasion and metastasis. In particular, ErbB2 and EGFR 
have been implicated in development of many types 
of human cancer [3, 4, 6]. Genetic changes that have 
been detected in human tumors include gene ampli-
fication leading to receptor overexpression, activating 
kinase domain mutations mainly in EGFR, but also 
in ErbB2, in-frame deletions in the extracellular domain 
of EGFR (EGFR vIII), and coexpression of ErbB ligands 
and receptors in tumors. Each alteration promotes 
constitutive activation of the receptors. 
CROSS-TALK OF TGFβ AND EGF 
IN CANCER
Signaling pathways do not act in isolation, but 
interplay with each other and form complex signaling 
networks. Recent studies have shown that ErbB signal-
ing, which activates both the MAPK (including Erk1/2, 
JNK1/2/3, and p38/MAPKs) and phosphatidylino-
sitol-3 kinase (PI3K)/Akt pathways, communicates 
intimately with TGFβ/Smad in controlling mammary 
epithelial cell biology and breast cancer development 
[7]. Other common Smad-dependent regulatory 
mechanisms include phosphorylation of Smad2 and 
Smad3 by PKC and PKG. MAPKs and Akt bind to and/
or phosphorylate Smads to control their intracellular 
distribution and transcriptional activity [2, 7]. MAPKs 
and Akt also phosphorylate and regulate a variety 
of Smad binding partners in the nucleus, indirectly 
affecting the Smads. We focus below on the cross-talk 
involving TGF and Smads from one side, and MAPK 
and Akt from the other side (Fig. 3).
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Fig. 3. Cross-talk between TGFβ and EGF signaling pathway. The 
MAPK and PI3K/Akt are linkers (common targets) of TGFβ and 
EGF pathways. Their interplay is modulated primarily by Smad 
functions. MAPKs and Akt bind and/or phosphorylate R-Smads 
to control their intracellular distribution and transcriptional ac-
tivity. MAPKs and Akt also phosphorylate and regulate a variety 
of Smad binding partners in the nucleus, indirectly affecting 
the Smads. TGFβ stimulates Erk1/2 activation by regulating 
Plag1 and CNK.
TGFβ/SMADS AND THE ERBB/MAPK 
PATHWAY
A consensus is that HER2/Ras can antagonize 
TGFβ-induced apoptosis and cell cycle arrest, while al-
lowing for the pro-migratory and pro-invasive functions 
of TGFβ. Therefore, both positive and negative regu-
lations exist between the two pathways. The synergy 
between the TGFβ and HER2/Ras/MAPK pathways 
often leads to the secretion of TGFβ, which in turn 
promote epithelial-to-mesenchymal transition (EMT) 
and cell invasion, whereas JNK kinases seem to nega-
tively regulate the autocrine expression of TGFβ1 [7, 
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8]. MEK/Erk has been reported to positively regulate 
SMAD3 gene transcription in epithelial and smooth 
muscle cells [7]. 
It has been confirmed that the linker region in Smad 
proteins is important for integrating ErbB/MAPK 
signals with the TGFβ pathway. Human cancer cells 
overexpressing oncogenic Ras are often resistant 
to TGFβ-induced cytostasis. MAPK/Erk-mediates 
Smad2/3 linker phosphorylation and Smad nuclear 
exclusion, which is considered as the reason for the 
attenuation of TGFβ induced cytostasis by MAPK 
[9]. MAPKs (especially Erk1/2) also phosphorylate 
the linker of Smad1/5, which almost always blocks 
Smad1/5 nuclear translocation. Phosphorylation 
in Smad1 linker region by Erk creates a docking site 
for the Smad1/5-specific E3 ubiquitin ligase, Smurf1. 
Smurf1 binding not only causes ubiquitination and 
degradation of the Smads but also occludes their 
interaction with the nuclear pore complex, thereby 
preventing Smad nuclear translocation [9]. In addition 
to R-Smads, MAPKs also phosphorylate and regulate 
the Co-Smad, Smad4, and the inhibitory Smad7. For 
instance, MAPK/Erk decreases Smad4 protein stability 
[9]. JNK and p38 seem to preferentially phosphorylate 
tumor-derived mutant Smad4 and promote its protea-
somal degradation http://www.nature.com/ cr/jour-
nal/v19/ n1/full/cr2008302a.html - bib58. Erk, JNK, 
and p38 have all been implicated in the transcriptional 
regulation of Smad7, therefore indirectly regulating 
TGFβ signaling. On the flip side, TGFβ also regulates 
MAPK/Erk signaling. Addition of TGFβ stimulates 
Erk1/2 activation in most of the cells. Our lab identi-
fied Plag1 and CNK contribution to TGFβ induced 
Erk1/2 activation [8].
MAPKs phosphorylate a number of nuclear tran-
scription factors, many of which can physically interact 
with Smads and regulate TGFβ responses. The best-
characterized ones in this category are the AP-1 pro-
teins, including members of the Jun, Fos, Maf, and 
ATF sub-families [9]. Functional interaction between 
Smad and the Jun/Fos family proteins has been widely 
studied, and their relationship can be synergistic 
or antagonistic depending on their target genes and 
other binding partners. Thus, TGFβ and EGF may 
coordinate their actions by the cross-talk between 
Smad-dependent signaling and Erk1/2 activation.
TGFβ AND THE ERBB/PI3K/AKT PATHWAY
PI3K pathway promotes cell survival, growth, 
and motility through Akt-mediated phosphorylation 
of a number of proteins. Oncogenic mutations and 
protein overproduction of PI3K and Akt are commonly 
found in human cancers. The activity of PI3K is coun-
teracted by the tumor suppressor protein PTEN. Loss-
of-function mutations of PTEN also occur at a high 
frequency in human cancers [7].
The PI3K/Akt activity is known to alleviate TGFβ-
induced apoptosis and/or cell cycle arrest in multiple 
types of cells. Interestingly, Smad3, but not Smad2, 
seems to be the primary target of inhibition by PI3K/
Akt, consistent with the indispensable function 
of Smad3 in mediating the pro-apoptotic effects 
of TGFβ. However, exactly how PI3K/Akt modulates 
Smad3 activation remains unanswered.
On the other hand, the PI3K/Akt pathway is also 
subjected to TGFβ regulation. Akt activity increases 
in response to TGFβ treatment, which seems to be re-
quired for a variety of TGFβ-induced activities, such 
as cell migration of HER2-expressing breast cancer 
cells, EMT of normal mammary epithelial cells, cell 
survival of mouse hippocampal neurons and mesen-
chymal cells, as well as growth stimulation of certain 
fibroblasts [7, 9]. It is to be noted that Akt activation 
by TGFβ is cell type-dependent and very likely indirect, 
often requiring either MAPKs or autocrine actions 
of secreted molecules.
Alteration of PTEN function represents another 
route for TGFβ to influence Akt activity. TGFβ has 
been shown to transcriptionally downregulate PTEN 
in Smad4 null pancreatic cancer cells, which, again, 
seems to rely on the function of the Ras/MAPK path-
way [7, 8, 9]. In the same cells, TGFβ elicits EMT 
by dislodging β-catenin from the adherence junctions, 
a process that involves TGFβ-dependent PTEN dis-
sociation from β-catenin and Akt activation. On the 
other hand, TGFβ/Smad can reduce Akt activity in he-
matopoietic cells by inducing the expression of SHIP 
(SH2 domain-containing 5’ inositol phosphatase), 
a lipid phosphatase that removes the 5 position phos-
phate from PIP3. 
TARGETING TGFβ AND EGF PATHWAYS 
IN CANCER TREATMENT
The genetic and preclinical studies support target-
ing TGFβ signaling as therapeutic strategy for combat-
ing cancer. To date there have been investigated three 
approaches to inhibit the TGFβ signaling. They are: 
(1) inhibition at the translational level using antisense 
oligonucleotides, (2) inhibition of the ligand-receptor 
interaction using monoclonal antibodies, and (3) in-
hibition of the receptor-mediated signaling cascade 
using inhibitors of TGFβ receptor kinases [1, 2]. For 
each of these approaches, several drugs have been 
developed and are either in pre-clinical or in early 
stages of clinical trials. Some of these have already 
been shown to be efficacious in limiting tumor inva-
sion and metastasis in vivo. Among these drugs are 
antisence oligos used for treatment of gliomas, and 
TβR-I kinase inhibitors used for treatment breast 
cancer. One of the challenges of anti-TGFβ therapy 
will be in targeting the tumor promoting arm of TGFβ 
signaling while maintaining the tumor suppressive arm. 
EGFR and ErbB receptors have been especially 
explored as targets for cancer treatments, because 
overexpression and mutations of these receptors 
are frequently observed in human malignancies. 
A variety of small molecule kinase inhibitors target-
ing EGFR (e.g. erlotinib: Tarceva™) and monoclonal 
antibodies targeting EGFR (e.g. cetuximab: Erbitux) 
and HER2 (e.g. trastuzumab: Herceptin™) have been 
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developed and some of them are used for treatment 
of lung and breast cancer [3]. Anti-EGFR therapy has 
shown significant efficacy for some patients. However, 
no therapeutic response was seen in high number 
of other cancer patients. In addition, patients initially 
responsive to anti-EGFR therapy develop resistance 
over time of treatment. Potential mechanisms of re-
sistance to EGFR-targeted therapy may be depen-
dent on EGFR gene amplification and mutations, and 
on activation of alternative signaling pathways which 
bypass the EGFR pathway.
Using targeted agents to inhibit multiple signaling 
pathways has emerged as a new paradigm for antican-
cer treatment. This approach is based on preclinical 
and clinical data showing potent anti-tumor activity 
of single drugs inhibiting multiple molecular targets 
or combination therapies involving multiple drugs with 
selective or narrow target specificity [10]. In a study 
comparing the multi-targeting tyrosine kinase in-
hibitor SU11248—whose targets include VEGFR and 
PDGFR—with agents targeting only PDGFR (imatinib) 
or VEGFR (SU10944) in mouse xenograft models, 
the most robust anti-tumor and anti-angiogenic ef-
fects were observed with SU11248. Moreover, the 
efficacy of imatinib combined with SU10944 was 
generally similar to that of SU11248 monotherapy, 
suggesting that the anti-tumor and anti-angiogenic 
effects of SU11248 included additional effects related 
to VEGFR and PDGFR inhibition [10]. This suggests 
that optimal therapeutic approaches to cancer may in-
volve targeting multiple molecules in different signaling 
pathways. Therefore, combination of drugs targeting 
EGF and TGFβ or development of drugs targeting com-
mon components of both pathways  may confer better 
therapeutic effects than single treatments.
ACKNOWLEDGEMENT
This work was supported by the Swedish Research 
Council, the Swedish Institute, and the Swedish Can-
cer Foundation to S.S.
REFERENCES
1. ten Dijke P, Hill CS. New insights into TGF-β-Smad 
signalling. Trends Biochem Sci 2004; 29: 265–73.
2. Massagué J. TGFβ in cancer. Cell 2008; 134: 215–30.
3. Scaltriti M, Baselga J. The epidermal growth factor 
receptor pathway: a model for targeted therapy. Clin Cancer 
Res 2006; 12: 5268–72.
4. Lurje G, Lenz HJ. EGFR signaling and drug discovery. 
Oncology 2009; 77: 400–10.
5. Derynck R, Zhang YE. Smad-dependent and Smad-
independent pathways in TGF-beta family signalling. Nature 
2003; 425: 577–84.
6. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal 
growth factor-related peptides and their receptors in human 
malignancies. Crit Rev Oncol Hematol 1995; 19: 183–232. 
7. Kretzschmar M, Doody J, Timokhina I, et al. A mecha-
nism of repression of TGFbeta/Smad signaling by oncogenic 
Ras. Genes Dev 1999; 13: 804–16. 
8. Bhaskaran N, Souchelnytskyi S. Systemic analysis of 
TGFbeta proteomics revealed involvement of Plag1/CNK1/
RASSF1A/Src network in TGFbeta1-dependent activation of 
Erk1/2 and cell proliferation. Proteomics 2008; 8: 4507–20.
9. Guo X, Wang XF. Signaling cross-talk between TGF-β/
BMP and other pathways. Cell Research 2009; 19: 71–88.
10. Faivre S, Djelloul S, Raymond E. New paradigms in 
anticancer therapy: targeting multiple signaling pathways with 
kinase inhibitors. Semin Oncol 2006; 33: 407–20.
Copyright © Experimental Oncology, 2011
